Cytomegalovirus Infection Treatment Market: Global Market Estimation, Dynamics, Regional Share, Trends, Competitor Analysis 2013 to 2017 and Forecast 2018 to 2024

Date : Apr 2018

Formats :
Report Code : PMR83649612

Category : Pharmaceutical and Healthcare
No Of Pages :
Global Cytomegalovirus Infection Treatment Market

Cytomegalovirus CMV infection is the common herpes virus infection having different symptoms which occurs in all ages of people around the world. Cytomegalovirus CMV infection is a communicable and easily prone through the body fluids like urine, saliva, blood, breast milk and semen. The infection may spread fast from urine or saliva from people who are infected with CMV having virus in their bodily fluids. The disease can transmit from pregnant to baby during delivery. Organ transplant and Blood transfusion are the other way for the transmission of the disease.

Cytomegalovirus infection treatment market is mainly propelling by the rise in the prevalence of CMV infections, growing awareness about herpes disease, pipeline drugs which are promising by key market players for the treatment of CMV infection. Moreover, rise in the support of government, and development of healthcare infrastructure are anticipated to fuel the growth of CMV infection treatment market. However, recent expiries of patented drugs, generic drugs that are available for the treatment like Ganciclovir & Foscarnet are anticipated to hamper the market growth of cytomegalovirus infection treatment.

The global cytomegalovirus infection market is classified on the basis of drug class, infection, distribution channel, and geography.

Based on drug class, the global cytomegalovirus infection market is segmented into the following:
Antiviral drugs
Foscarnet
Cytovene
Vistide
Others

Based on infection, the global cytomegalovirus infection market is segmented into the following
Retinitis
Pneumonia
Gastroenteritis
Others Mouth Ulcers, Pharyngitis, etc.

Based on distribution channel, the global cytomegalovirus infection market is segmented into the following:
Hospital Pharmacies
Retail Pharmacies
Others

Global cytomegalovirus infection treatment market is anticipated to show effective growth rate in foresee period. Players in the market are heavily investing in R&D for the development of novel therapies and drugs to treat cytomegalovirus infection. Moreover, regulatory bodies of the healthcare sector are having more attention on novel drugs by giving faster approvals and special status for the drugs. For instance, Merck & Co. Inc., developed Letermovir, antiviral drug for the treatment of CMV infection. The drug has received fast track status by the U.S. FDA and the orphan drug status by European Medicines Agency.

On the basis of Geographical regions, CMV infection treatment market is classified as into five key regions as Europe, Asia Pacific, North America, Middle East & Africa and Latin America. North America & Europe were anticipated to contribute major share in the cytomegalovirus infection treatment market due to the high prevalence rate of cytomegalovirus infection. As per Centre for Disease Control and Prevention CDC, approximately, 80,000 cases of CMV infections were diagnosed in U.S. and Europe. Increased prevalence of cytomegalovirus CMV infection in the developing countries and in the areas of lower economic status. AsiaPacific is anticipated to grow rapidly owing to the large patient pool, and rise in prevalence of many infectious diseases as well as rise in the awareness on cytomegalovirus infections.

Some of the players in cytomegalovirus infection market are F. HoffmannLa Roche AG Switzerland, GlaxoSmithKline plc U.K., Merck & Co., Inc. U.S., AiCuris Antiinfective Cures GmbH Germany Vical, Inc. U.S., Chimerix, Inc. U.S. and ViroPharma U.S., to name a few

In Feb 2018, Merck & Co., Inc. started pivotal Phase 3 clinical study of letermovir, an antiviral investigational drug for treating clinically significant cytomegalovirus Infectio
1. Executive Summary
2. Global Cytomegalovirus Infection Treatment Market Introduction
2.1. Global Cytomegalovirus Infection Treatment Market – Taxonomy
2.2. Global Cytomegalovirus Infection Treatment Market –Definitions
2.2.1. Drug Type
2.2.2. Distribution Channel
3. Global Cytomegalovirus Infection Treatment Market Dynamics
3.1. Drivers
3.2. Restraints
3.3. Opportunities/Unmet Needs of the Market
3.4. Trends
3.5. Global Cytomegalovirus Infection Treatment Market Dynamic Factors Impact Analysis
4. Global Cytomegalovirus Infection Treatment Market Analysis, 2013 – 2017 and Forecast, 2018 – 2024
4.1. Market Analysis, 2013 2017 and Forecast, 2018 – 2024 Revenue, USD Mn
4.2. YearoverYear YoY Growth Analysis %
4.3. Market Opportunity Analysis
5. Global Cytomegalovirus Infection Treatment Market, By Drug Type, 2013 2017 and Forecast, 2018 – 2024 Revenue, USD Mn
5.1. Foscarnet
5.1.1. Market Analysis, 2013 2017 and Forecast, 2018 – 2024 Revenue, USD Mn
5.1.2. YearoverYear YoY Growth Analysis % and Market Share Analysis %
5.1.3. Market Opportunity Analysis
5.2. Cytovene
5.2.1. Market Analysis, 2013 2017 and Forecast, 2018 – 2024 Revenue, USD Mn
5.2.2. YearoverYear YoY Growth Analysis % and Market Share Analysis %
5.2.3. Market Opportunity Analysis
5.3. Vistide
5.3.1. Market Analysis, 2013 2017 and Forecast, 2018 – 2024 Revenue, USD Mn
5.3.2. YearoverYear YoY Growth Analysis % and Market Share Analysis %
5.3.3. Market Opportunity Analysis
5.4. Others
5.4.1. Market Analysis, 2013 2017 and Forecast, 2018 – 2024 Revenue, USD Mn
5.4.2. YearoverYear YoY Growth Analysis % and Market Share Analysis %
5.4.3. Market Opportunity Analysis
6. Global Cytomegalovirus Infection Treatment Market, By Infection, 2013 2017 and Forecast, 2018 – 2024 Revenue, USD Mn
6.1. Retinitis
6.1.1. Market Analysis, 2013 2017 and Forecast, 2018 – 2024 Revenue, USD Mn
6.1.2. YearoverYear YoY Growth Analysis % and Market Share Analysis %
6.1.3. Market Opportunity Analysis
6.2. Pneumonia
6.2.1. Market Analysis, 2013 2017 and Forecast, 2018 – 2024 Revenue, USD Mn
6.2.2. YearoverYear YoY Growth Analysis % and Market Share Analysis %
6.2.3. Market Opportunity Analysis
6.3. Gastroenteritis
6.3.1. Market Analysis, 2013 2017 and Forecast, 2018 – 2024 Revenue, USD Mn
6.3.2. YearoverYear YoY Growth Analysis % and Market Share Analysis %
6.3.3. Market Opportunity Analysis
6.4. Others Mouth Ulcers, Pharyngitis, etc.
6.4.1. Market Analysis, 2013 2017 and Forecast, 2018 – 2024 Revenue, USD Mn
6.4.2. YearoverYear YoY Growth Analysis % and Market Share Analysis %
6.4.3. Market Opportunity Analysis
7. Global Cytomegalovirus Infection Treatment Market, By Distribution Channel, 2013 2017 and Forecast, 2018 – 2024 Revenue, USD Mn
7.1. Hospital Pharmacies
7.1.1. Market Analysis, 2013 2017 and Forecast, 2018 – 2024 Revenue, USD Mn
7.1.2. YearoverYear YoY Growth Analysis % and Market Share Analysis %
7.1.3. Market Opportunity Analysis
7.2. Retail Pharmacies
7.2.1. Market Analysis, 2013 2017 and Forecast, 2018 – 2024 Revenue, USD Mn
7.2.2. YearoverYear YoY Growth Analysis % and Market Share Analysis %
7.2.3. Market Opportunity Analysis
7.3. Online Pharmacies
7.3.1. Market Analysis, 2013 2017 and Forecast, 2018 – 2024 Revenue, USD Mn
7.3.2. YearoverYear YoY Growth Analysis % and Market Share Analysis %
7.3.3. Market Opportunity Analysis
8. Global Cytomegalovirus Infection Treatment Market Forecast, By Region, 2013 2017 and Forecast, 2018 – 2024 Revenue, USD Mn
8.1. North America
8.1.1. Market Analysis, 2013 2017 and Forecast, 2018 – 2024 Revenue, USD Mn
8.1.2. YearoverYear YoY Growth Analysis % and Market Share Analysis %
8.1.3. Market Opportunity Analysis
8.2. Europe
8.2.1. Market Analysis, 2013 2017 and Forecast, 2018 – 2024 Revenue, USD Mn
8.2.2. YearoverYear YoY Growth Analysis % and Market Share Analysis %
8.2.3. Market Opportunity Analysis
8.3. AsiaPacific
8.3.1. Market Analysis, 2013 2017 and Forecast, 2018 – 2024 Revenue, USD Mn
8.3.2. YearoverYear YoY Growth Analysis % and Market Share Analysis %
8.3.3. Market Opportunity Analysis
8.4. Latin America
8.4.1. Market Analysis, 2013 2017 and Forecast, 2018 – 2024 Revenue, USD Mn
8.4.2. YearoverYear YoY Growth Analysis % and Market Share Analysis %
8.4.3. Market Opportunity Analysis
8.5. Middle East and Africa
8.5.1. Market Analysis, 2013 2017 and Forecast, 2018 – 2024 Revenue, USD Mn
8.5.2. YearoverYear YoY Growth Analysis % and Market Share Analysis %
8.5.3. Market Opportunity Analysis
8.6. Global Cytomegalovirus Infection Treatment Market Opportunity Analysis Index, By Drug Type, By Infection, By Distribution Channel, and Region, 2018 – 2024
9. North America Cytomegalovirus Infection Treatment Market Analysis, 2013 2017 and Forecast, 2018 – 2024 Revenue, USD Mn
9.1. Drug Type Analysis 2013 2017 and Forecast 2018 – 2024 by Revenue USD Mn, YoY Growth %, and Market Share %
9.1.1. Antiviral drugs
9.1.1.1. Foscarnet
9.1.1.2. Cytovene
9.1.1.3. Vistide
9.1.1.4. Others
9.2. Infection Analysis 2013 2017 and Forecast 2018 – 2024 by Revenue USD Mn, YoY Growth %, and Market Share %
9.2.1. Retinitis
9.2.2. Pneumonia
9.2.3. Gastroenteritis
9.2.4. Others Mouth Ulcers, Pharyngitis, etc.
9.3. Distribution Channel Analysis 2013 2017 and Forecast 2018 – 2024 by Revenue USD Mn, YoY Growth %, and Market Share %
9.3.1. Hospital Pharmacies
9.3.2. Retail Pharmacies
9.3.3. Online Pharmacies
9.4. Country Analysis 2017 and Forecast 2018 – 2024 by Revenue USD Mn YoY Growth % and Market Share %
9.4.1. U.S.
9.4.2. Canada
9.5. North America Cytomegalovirus Infection Treatment Market Opportunity Analysis Index, By Drug Type, By Infection, By Distribution Channel, and Country, 2018 – 2024
9.6. North America Cytomegalovirus Infection Treatment Market Dynamics – Trends
10. Europe Cytomegalovirus Infection Treatment Market Analysis, 2013 2017 and Forecast, 2018 – 2024 Revenue, USD Mn
10.1. Drug Type Analysis 2013 2017 and Forecast 2018 – 2024 by Revenue USD Mn, YoY Growth %, and Market Share %
10.1.1. Antiviral drugs
10.1.1.1. Foscarnet
10.1.1.2. Cytovene
10.1.1.3. Vistide
10.1.1.4. Others
10.2. Infection Analysis 2013 2017 and Forecast 2018 – 2024 by Revenue USD Mn, YoY Growth %, and Market Share %
10.2.1. Retinitis
10.2.2. Pneumonia
10.2.3. Gastroenteritis
10.2.4. Others Mouth Ulcers, Pharyngitis, etc.
10.3. Distribution Channel Analysis 2013 2017 and Forecast 2018 – 2024 by Revenue USD Mn, YoY Growth %, and Market Share %
10.3.1. Hospital Pharmacies
10.3.2. Retail Pharmacies
10.3.3. Online Pharmacies
10.4. Country Analysis 2013 2017 and Forecast 2018 – 2024 by Revenue USD Mn YoY Growth % and Market Share %
10.4.1. Germany
10.4.2. UK
10.4.3. France
10.4.4. Spain
10.4.5. Italy
10.4.6. Russia
10.4.7. Poland
10.4.8. Rest of Europe
10.5. Europe Cytomegalovirus Infection Treatment Market Opportunity Analysis Index, By Drug Type, By Infection, By Distribution Channel, and Country, 2018 – 2024
10.6. Europe Cytomegalovirus Infection Treatment Market Dynamics – Trends
11. AsiaPacific Cytomegalovirus Infection Treatment Market Analysis, 2013 2017 and Forecast, 2018 – 2024 Revenue, USD Mn
11.1. Drug Type Analysis 2013 2017 and Forecast 2018 – 2024 by Revenue USD Mn, YoY Growth %, and Market Share %
11.1.1. Antiviral drugs
11.1.1.1. Foscarnet
11.1.1.2. Cytovene
11.1.1.3. Vistide
11.1.1.4. Others
11.2. Infection Analysis 2013 2017 and Forecast 2018 – 2024 by Revenue USD Mn, YoY Growth %, and Market Share %
11.2.1. Retinitis
11.2.2. Pneumonia
11.2.3. Gastroenteritis
11.2.4. Others Mouth Ulcers, Pharyngitis, etc.
11.3. Distribution Channel Analysis 2013 2017 and Forecast 2018 – 2024 by Revenue USD Mn, YoY Growth %, and Market Share %
11.3.1. Hospital Pharmacies
11.3.2. Retail Pharmacies
11.3.3. Online Pharmacies
11.4. Country Analysis 2013 2017 and Forecast 2018 – 2024 by Revenue USD Mn YoY Growth % and Market Share %
11.4.1. Japan
11.4.2. China
11.4.3. India
11.4.4. ASEAN
11.4.5. Australia & New Zealand
11.4.6. Rest of AsiaPacific
11.5. AsiaPacific Cytomegalovirus Infection Treatment Market Opportunity Analysis Index, By Drug Type, By Infection, By Distribution Channel, and Country, 2018 – 2024
11.6. AsiaPacific Cytomegalovirus Infection Treatment Market Dynamics – Trends
12. Latin America Cytomegalovirus Infection Treatment Market Analysis, 2013 2013 2013 2017 and Forecast, 2018 – 2024 Revenue, USD Mn
12.1. Drug Type Analysis 2013 2017 and Forecast 2018 – 2024 by Revenue USD Mn, YoY Growth %, and Market Share %
12.1.1. Antiviral drugs
12.1.1.1. Foscarnet
12.1.1.2. Cytovene
12.1.1.3. Vistide
12.1.1.4. Others
12.2. Infection Analysis 2013 2017 and Forecast 2018 – 2024 by Revenue USD Mn, YoY Growth %, and Market Share %
12.2.1. Retinitis
12.2.2. Pneumonia
12.2.3. Gastroenteritis
12.2.4. Others Mouth Ulcers, Pharyngitis, etc.
12.3. Distribution Channel Analysis 2013 2017 and Forecast 2018 – 2024 by Revenue USD Mn, YoY Growth %, and Market Share %
12.3.1. Hospital Pharmacies
12.3.2. Retail Pharmacies
12.3.3. Online Pharmacies
12.4. Country Analysis 2013 2017 and Forecast 2018 – 2024 by Revenue USD Mn YoY Growth % and Market Share %
12.4.1. Brazil
12.4.2. Mexico
12.4.3. Argentina
12.4.4. Venezuela
12.4.5. Rest of Latin America
12.5. Latin America Cytomegalovirus Infection Treatment Market Opportunity Analysis Index, By Drug Type, By Infection, By Distribution Channel, and Country, 2018 – 2024
12.6. Latin America Cytomegalovirus Infection Treatment Market Dynamics – Trends
13. Middle East and Africa Cytomegalovirus Infection Treatment Market Analysis, 2013 2017 and Forecast, 2018 – 2024 Revenue, USD Mn
13.1. Drug Type Analysis 2013 2017 and Forecast 2018 – 2024 by Revenue USD Mn, YoY Growth %, and Market Share %
13.1.1. Antiviral drugs
13.1.1.1. Foscarnet
13.1.1.2. Cytovene
13.1.1.3. Vistide
13.1.1.4. Others
13.2. Infection Analysis 2013 2017 and Forecast 2018 – 2024 by Revenue USD Mn, YoY Growth %, and Market Share %
13.2.1. Retinitis
13.2.2. Pneumonia
13.2.3. Gastroenteritis
13.2.4. Others Mouth Ulcers, Pharyngitis, etc.
13.3. Distribution Channel Analysis 2013 2017 and Forecast 2018 – 2024 by Revenue USD Mn, YoY Growth %, and Market Share %
13.3.1. Hospital Pharmacies
13.3.2. Retail Pharmacies
13.3.3. Online Pharmacies
13.4. Country Analysis 2013 2017 and Forecast 2018 – 2024 by Revenue USD Mn YoY Growth % and Market Share %
13.4.1. Gulf Cooperation Council GCC Countries
13.4.2. Israel
13.4.3. South Africa
13.4.4. Rest of MEA
13.5. MEA Cytomegalovirus Infection Treatment Market Opportunity Analysis Index, By Drug Type, By Infection, By Distribution Channel, and Country, 2018 – 2024
13.6. MEA Cytomegalovirus Infection Treatment Market Dynamics – Trends
14. Competition Landscape
14.1. Strategic Dashboard of Top Market Players
14.2. Company Profiles Introduction, Financial Analysis, Product & Service Offerings, Key Developments, Strategies, and SWOT Analysis
14.2.1. F. HoffmannLa Roche AG Switzerland
14.2.2. GlaxoSmithKline plc U.K.
14.2.3. Merck & Co., Inc. U.S.
14.2.4. AiCuris Antiinfective Cures GmbH Germany
14.2.5. Vical, Inc. U.S.
14.2.6. Chimerix, Inc. U.S.
14.2.7. ViroPharma U.S.
15. Research Methodology
16. Key Assumptions and Acronyms
  Purchase Options for Report

Need More information

Call us :
USA : +1 7162260907
UK : +44 7441952057
....
sales@planetmarketreports.com

Why to PMR

PMR Market Research

Our syndicated research reports cover 50+ industry sectors offering you product and country wise breakup of the market along with niche data and insights that will help you make informed business decision. Our research is focused on the key segments of an industry that possess opportunities of growth.

  • Industrial ...
  • Business ....
  • Consumer ....
  • Peer ....